Cumberland Pharmaceuticals Inc SEC Filings

James Jones, identified as a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of systematic purchases of the issuer's common stock during July 2025. The table discloses multiple acquisitions executed across July 1–31, 2025, with reported transaction prices ranging from $3.05 to $3.82 per share. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

The Form shows the reporting person’s beneficial ownership rising through the month, culminating at 43,676 shares following the July 31, 2025 purchase. The filing was signed by an attorney-in-fact on behalf of James Jones and discloses the transactions as purchases under the Section 16 reporting requirements.

A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals (CPIX), reported a series of purchases of the company's common stock executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Transactions recorded in the Form 4 run from July 1 through July 31, 2025 at prices shown in the filing ranging from $3.05 to $3.82.

All reported shares are held directly. After the reported transactions, the Form 4 shows beneficial ownership of 5,699,768 shares. The filing identifies the reporting person as a Director, Chairman and CEO and a 10% owner, and notes the purchases occurred automatically pursuant to the 10b5-1 plan.

Kenneth J. Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), executed a series of automated purchases of the company's common stock during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Over 22 trading dates from July 1 to July 31, the reporting shows purchases totaling 1,712 shares, increasing his direct beneficial ownership to 288,345 shares. Transaction prices ranged from $3.05 to $3.82, with individual daily purchases of mostly 80 shares and later 68 shares.

The Form 4 indicates these purchases were made automatically pursuant to the previously adopted 10b5-1 plan and that ownership is held directly. No derivative transactions or other classes of securities are reported on this filing.

Cumberland Pharmaceuticals reported six-month net revenues of $22.55 million, up from $18.35 million a year earlier, driven mainly by higher sales of Sancuso, Vibativ, Caldolor and Acetadote, while Kristalose sales declined. For the six months ended June 30, 2025 the company recorded a $512,977 net income versus a $3.01 million loss a year earlier, reflecting improved operating results and a $3.0 million milestone recognized related to Vibativ.

Cash and liquidity show $16.09 million in cash, positive operating cash flow of $4.74 million for the six months, and working capital of $7.23 million. Borrowings under the revolving credit facility were $5.24 million at June 30, 2025 (down from $15.3 million at year-end). Clinical and commercial developments include Phase II ifetroban results (a reported 5.4% cardiac improvement in DMD), an upcoming FDA meeting, new Vibativ supply/pack configurations and a published pharmacokinetic analysis supporting dosing.

SEC Form 4 filing dated 07/11/2025 reports a series of open-market purchases of Cumberland Pharmaceuticals Inc. (CPIX) common stock by director Caroline Young.

Transaction details:

• 20 separate buy transactions executed from 06/02/2025 to 06/30/2025.
• Total shares acquired: 84 (nineteen lots of 4 shares and one lot of 8 shares).
• Price range: $2.60 – $6.00 per share.
• Weighted-average purchase price: approximately $4.81 per share (derived from disclosed price and share data).
• Total cost: about $403.60.

All trades were automatically executed under a Rule 10b5-1 trading plan adopted on 11/14/2024, as noted in the Explanation of Responses.

Following the reported transactions Ms. Young’s direct beneficial ownership stands at 32,653 CPIX shares. No derivative security activity was reported, and the filing indicates that Ms. Young continues to serve as a director of the company.

The filing does not provide information on company operations, earnings or additional insider activity. The share-price pattern shows a steady decline over the month—from $5.20 on 06/02 to $2.74 on 06/30—suggesting the purchases occurred during a period of price weakness.

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 filing, 11 Jul 2025

Chairman, CEO and 10% owner A. J. Kazimi reported a series of open-market purchases carried out automatically under a Rule 10b5-1 trading plan adopted on 14 Nov 2024. Between 02 Jun 2025 and 30 Jun 2025 he bought about 160 common shares in 20 small daily lots (mostly 8 shares, last lot 16 shares). Purchase prices ranged from $6.00 at the start of the period to $2.60 at month-end, implying an average cost close to $5.0 per share (≈ $800 total).

Kazimi’s direct beneficial ownership increased from 5,699,268 to 5,699,428 shares. No derivative securities were involved. Because the transactions represent <0.003% of his existing stake and were pre-scheduled, the filing is largely administrative, although consistent insider buying—despite the share-price decline—can be viewed as a minor vote of confidence.

Form 4 filing for Cumberland Pharmaceuticals Inc. (CPIX) details a series of open-market purchases executed by director Kenneth J. Krogulski under an existing Rule 10b5-1 trading plan adopted on 14 Nov 2024.

• Transaction window: 2 Jun 2025 – 30 Jun 2025 (20 trading days).
• Shares acquired: 935 common shares (19 trades of 45 shares each and one trade of 80 shares).
• Total cost basis: purchase prices ranged from $2.60 – $6.00 per share, indicating declining market prices over the period.
• Ownership change: holdings rose from 285,743 to 286,633 shares, a 0.3% increase.
• Transaction code “P” confirms open-market purchases; the “V” footnote references execution under the 10b5-1 plan.

No derivative securities were reported, and there were no dispositions. The filing is routine in nature and does not announce any corporate events, earnings data, or material changes beyond the incremental insider accumulation.